Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Lyell Immunopharma (LYEL) Equity Average: 2020-2025

Historic Equity Average for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $314.0 million.

  • Lyell Immunopharma's Equity Average fell 42.76% to $314.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.0 million, marking a year-over-year decrease of 42.76%. This contributed to the annual value of $518.9 million for FY2024, which is 30.27% down from last year.
  • Lyell Immunopharma's Equity Average amounted to $314.0 million in Q3 2025, which was down 1.16% from $317.7 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Equity Average high stood at $1.0 billion for Q3 2021, and its period low was -$313.3 million during Q1 2021.
  • Moreover, its 3-year median value for Equity Average was $584.8 million (2024), whereas its average is $561.2 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Equity Average surged by 496.33% in 2021, and later crashed by 45.67% in 2025.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Equity Average stood at $958.1 million in 2021, then declined by 13.72% to $826.6 million in 2022, then decreased by 18.19% to $676.3 million in 2023, then crashed by 32.46% to $456.8 million in 2024, then slumped by 42.76% to $314.0 million in 2025.
  • Its Equity Average was $314.0 million in Q3 2025, compared to $317.7 million in Q2 2025 and $359.7 million in Q1 2025.